No Data
No Data
Analysts Conflicted on These Healthcare Names: Revolution Medicines (RVMD), Personalis (PSNL) and Zimmer Biomet Holdings (ZBH)
Personalis Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results.
Buy Rating Reaffirmed for Personalis Amid Robust Revenue Growth and Optimistic MRD Test Market Penetration
Express News | Personalis Inc : Needham Raises Target Price to $5.5 From $3.5
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Revolution Medicines (RVMD) and Personalis (PSNL)
TD Cowen Keeps Their Buy Rating on Personalis (PSNL)
No Data
eternityawaits : New week! Let do it!